● In Stock
Ipamorelin
≥99% Purity | HPLC Verified
$40.00
PASSED
Sterility & Endotoxins
PASSED
Net Content & Purity
Purity:
≥99%
Store at
-20°C
Selective pentapeptide GH secretagogue studied for growth hormone release without cortisol elevation. Research use only.
| Strength | 5mg |
| molecular_formula | C38H49N9O5 |
| Molecular Weight | 711.85 g/mol |
| Purity | >99% (HPLC) |
| Form | Lyophilized Powder |
0%
Cortisol Elevation
No stress hormone activation vs GHRP-6
24%
Bone Growth
52 vs 42 μm/day (dose-dependent)
ED50
80 nmol/kg
GH release potency (vs GHRP-6: 115)
~2 hr
Half-Life
Human PK study — peak GH at 40 min
Mechanism of Action
How Ipamorelin Works
The first truly selective growth hormone secretagogue — GH release without cortisol, ACTH, or prolactin elevation
GHSR
GHSR-1a — Ghrelin Receptor
Selectively binds Growth Hormone Secretagogue Receptor 1a on anterior pituitary somatotrophs, triggering GH release in a highly selective, dose-dependent manner without off-target receptor activation
GH
Somatotroph Cells — Pituitary
Directly stimulates GH synthesis and release from anterior pituitary cells. No desensitization with repeated dosing. Preserves natural pulsatile GH secretion pattern — more physiologic than continuous release.
IGF-1
IGF-1 Axis — Downstream
Sustained GH release elevates IGF-1 levels in the liver, mediating the anabolic effects on tissue growth, protein synthesis, bone metabolism, and recovery
Selectivity Advantage
Ipamorelin vs Earlier GHRPs
Raun et al. 1998: Ipamorelin releases GH with higher potency than GHRP-6 (ED50 80 vs 115 nmol/kg) — while producing no significant cortisol, ACTH, or prolactin elevation even at 200 μg/kg
80
Ipamorelin ED50 (nmol/kg)
115
GHRP-6 ED50 (nmol/kg)
None
Cortisol / ACTH elevation
None
Prolactin / aldosterone rise
Clinical Research
What Research Has Shown
Preclinical efficacy and Phase II human safety data from Novo Nordisk research program
0%
Key Differentiator
Significant Cortisol Elevation
No cortisol, ACTH, or prolactin elevation observed · even at 200 μg/kg · Raun et al. Eur J Endocrinol 1998
Bone Growth Rate (μm/day)
Andersen et al. 2001 · Comparable to recombinant GH
Phase II POI Trial: AE Rates
Beck et al. 2014 · 117 patients · 0.03 mg/kg BID × 7 days
Side Effects (vs Other GHRPs)
No cortisol, ACTH, or prolactin effects at any dose studied.
📈
Research Applications
Documented effects from preclinical and Phase II clinical studies
Bone
Growth Research
24% increase in longitudinal bone growth rate — comparable to recombinant growth hormone
Well
Tolerated
Phase II AE rate (87.5%) similar to placebo (94.8%) — no serious drug-related adverse events
0%
Cortisol Impact
No significant cortisol, ACTH, or prolactin elevation — key advantage over all earlier GHRPs
54×
GH Synergy (+ CJC)
Combined with CJC-1295 produces 54× GH increase — 2.7× more than either alone
🦘 Bone Growth
Longitudinal Bone Research
Dose-dependent bone growth effects comparable to native growth hormone
Control growth rate42 μm/day
Ipamorelin (high dose)52 μm/day (+24%)
Increase vs control+10 μm/day
Comparable toRecombinant GH
Key finding: Ipamorelin's bone growth effects were dose-dependent and matched those of exogenous GH — confirming effective endogenous GH stimulation.
💪 Body Composition
Lean Mass & Recovery
Sustained GH and IGF-1 elevation supports body composition and tissue repair
Evening dosing: GH secretagogues taken before sleep amplify the natural nocturnal GH peak, potentially improving slow-wave sleep quality and overnight recovery.
💉 GI Motility Research
Post-Operative Ileus Trial
Phase II: Ipamorelin in surgical patients recovering from post-operative ileus
Trial size117 patients (RCT)
Dose0.03 mg/kg BID
Duration7 days
AE rate (drug)87.5% (vs 94.8% placebo)
Serious drug AEs0
Compound Specifications
Compound Information
Technical specifications for Ipamorelin (NNC 26-0161)
Molecular Profile
What Is Ipamorelin?
TypeSynthetic pentapeptide
CAS Number170851-70-4
Molecular FormulaC38H49N9O5
Molecular Weight711.85 g/mol
Amino Acids5
SequenceAib-His-D-2-Nal-D-Phe-Lys-NH2
Storage Requirements
Stability Information
Lyophilized (powder)2–8°C, 24+ months
Reconstituted2–8°C, 2–4 weeks
ReconstitutionBacteriostatic water
LightProtect from light
Freeze-thawAvoid repeated cycles
Purity (EON standard)>99% HPLC verified
Phase II CompletedWADA S2 Banned
Development Status
Where It Stands
DeveloperNovo Nordisk
Development CodeNNC 26-0161
Primary researchGH deficiency, GI motility
Clinical stagePhase II (POI trial)
FDA statusNot approved
WADABanned (S2)
Scientific Literature
Key Publications
Foundational research on Ipamorelin selectivity, bone growth, and clinical safety
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID: 9849822.
- Andersen NB, et al. Effects of ipamorelin on longitudinal bone growth in rats. Growth Horm IGF Res. 2001;11(4):223-9. PMID: 10373343.
- Beck DE, et al. Ipamorelin in the prevention of post-operative ileus. Dis Colon Rectum. 2014;57(2):192-9. PMID: 25331030.
- Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth. 1999;63(4):301-9. PMID: 10496658.
- Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 30186644.
Common Questions
Frequently Asked Questions
Common questions about Ipamorelin research
Ipamorelin is the first truly selective growth hormone secretagogue. Earlier GHRPs like GHRP-6 and GHRP-2 effectively release GH but also significantly elevate cortisol, ACTH, and prolactin — causing side effects like increased appetite, water retention, and stress hormone activation. Ipamorelin releases GH with higher potency (ED50 = 80 nmol/kg vs 115 for GHRP-6) but without these off-target effects, even at doses up to 200 μg/kg.
Human pharmacokinetic studies show Ipamorelin has a half-life of approximately 2 hours, with peak GH response at ~40 minutes (0.67 hours) after subcutaneous injection. The serum concentration required for 50% maximal GH response (SC50) is 214 nmol/L. This short half-life supports pulsatile dosing that mimics natural GH secretion patterns.
Yes. Ipamorelin activates the ghrelin receptor (GHSR-1a) while CJC-1295 activates GHRH receptors — two complementary and non-competing pathways. Research shows combining GHRH and GHRP pathways produces approximately 54× GH increase vs 20× (Ipamorelin alone) or 47× (CJC alone), with 43% faster time to peak. This synergistic combination is one of the most studied pairings in GH secretagogue research.
The most notable human trial was a Phase II study in 117 patients with post-operative ileus, where Ipamorelin (0.03 mg/kg BID for 7 days) was well-tolerated with adverse event rates similar to placebo (87.5% vs 94.8%). Human PK/PD studies have also characterized its GH-releasing pharmacokinetics. Developed by Novo Nordisk (NNC 26-0161), the compound has not progressed to Phase III trials.
Yes. Ipamorelin is a WADA Prohibited Substance classified under S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). It is banned both in-competition and out-of-competition in all sports. Athletes subject to drug testing should be aware that use of this compound will result in a positive test.
Published research on this compound is available through PubMed and other scientific databases.
Certificate of Analysis
| Analysis Date: | Available on request |
| Lot Number: | Batch-specific |
| Purity: | >99% (HPLC) |
Third-Party Testing
- ✓ Identity verification (Mass Spectrometry)
- ✓ Purity analysis (HPLC)
- ✓ Sterility testing
- ✓ Endotoxin screening
Storage Conditions
- Lyophilized: Store at -20°C, protected from light
- Reconstituted: Store at 2-8°C, use within 30 days
- Stability: 24 months from manufacture date when stored properly
Handling Guidelines
- Use sterile technique when reconstituting
- Allow vial to reach room temperature before opening
- Reconstitute with bacteriostatic water or sterile saline
- Avoid repeated freeze-thaw cycles
RESEARCH INSIGHTS
3D Structure
Ipamorelin
This compound has been extensively studied in peer-reviewed literature. Eon Peptides provides this product exclusively for legitimate in-vitro research and analytical applications.
- • High-purity research compound
- • Full analytical documentation included
- • Third-party verification available
PRODUCT SPECIFICATIONS
LOT DATA
| Lot Number | Assigned on shipment |
| Verified Purity | >99% |
| Quantity | 5mg |
MOLECULAR DATA
| Molecular Formula | Available on request |
| Form | Lyophilized Powder |
| Appearance | White to off-white powder |
Researchers who studied this also studied...
Related products
These products are intended for laboratory research purposes only, and are not for human or animal consumption.